Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free BMRN Stock Alerts

BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts

BioMarin Pharmaceutical logo
$54.12 -0.48 (-0.88%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$53.96 -0.16 (-0.29%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BioMarin Pharmaceutical Earnings Summary

BioMarin Pharmaceutical issued Q3 2025 earnings on October 27, 2025, reporting an EPS of $0.12, which missed analysts' consensus estimates of $0.32 by $0.20. Quarterly revenue rose 4.1% year-over-year to $776.13 million, below the consensus estimate of $782.42 million. With a trailing EPS of $1.37 and a P/E Ratio of 39.50, BioMarin Pharmaceutical's earnings are expected to grow 11.98% next year, from $4.34 to $4.86 per share.

Latest Q3
Earnings Date
Oct. 27Estimated
Consensus EPS
(Oct. 27)
$0.32
Actual EPS
(Oct. 27)
$0.12 Missed By -$0.20
Actual Revenue
(Oct. 27)
$776.13M

Q3 2025 Earnings Resources

Slide Deck

BioMarin Pharmaceutical's Q3 2025 Slide DeckFull Screen Slide Deck
Powered by Quartr
Get BioMarin Pharmaceutical Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioMarin Pharmaceutical and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

BMRN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BMRN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioMarin Pharmaceutical Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany EPS GuidanceCompany Revenue Guidance
Q1 20263$0.86$1.19$1.02
Q2 20263$0.89$1.28$1.09
Q3 20263$0.89$1.23$1.05
Q4 20263$0.91$1.35$1.12
FY 2026 12 $3.55 $5.05 $4.28
Q1 20271$1.15$1.15$1.15
Q2 20271$1.34$1.34$1.34
Q3 20271$1.30$1.30$1.30

BioMarin Pharmaceutical Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/27/2025Q3 2025$0.32$0.12 -$0.20-$0.16$782.42M$776.13M
2/19/2025Q4 2024$0.54$0.72+$0.18$0.64$711.05M$747.31M
10/29/2024Q3 2024$0.78$0.55 -$0.23$0.93$703.37M$746.00M
8/5/2024Q2 2024$0.38$0.77+$0.39$0.99$660.51M$712.03M

Data powered by Fiscal.ai.

BioMarin Pharmaceutical Earnings - Frequently Asked Questions

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earning data on Monday, October 27, 2025. Learn more on BMRN's earnings history.

BioMarin Pharmaceutical issued an update on its FY 2026 earnings guidance on Monday, May, 4th. The company provided earnings per share guidance of 4.850-5.05 for the period, compared to the consensus earnings per share estimate of 4.980. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.7 billion.

In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) missed the analysts' consensus estimate of $0.32 by $0.20 with a reported earnings per share (EPS) of $0.12. Learn more on analysts' earnings estimate vs. BMRN's actual earnings.

The conference call for BioMarin Pharmaceutical's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for BioMarin Pharmaceutical's latest earnings report can be read online.
Read Transcript

BioMarin Pharmaceutical's earnings report can be found in their filing with the SEC.
View SEC filing

BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $3.22 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $348.90 million. BMRN has generated $1.37 earnings per share over the last four quarters.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 39.50 and a forward price-to-earnings ratio of 12.47. The price/earnings-to-growth ratio is 0.39.

BioMarin Pharmaceutical's earnings are expected to grow from $4.34 per share to $4.86 per share in the next year, which is a 11.98% increase.

Related Companies
Earnings Tools

This page (NASDAQ:BMRN) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
Why I flew on a tiny helicopter next to a potential nuclear bomb target
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...
Altimetry | Sponsoredtc pixel